pSivida Corp Announces First Quarter FY 2016 Financial Results Release Date and Conference Call Information
October 30 2015 - 7:00AM
pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development
of sustained release drug delivery products for treating eye
diseases, today announced that its financial results for the first
quarter of fiscal year 2016 will be released after the market close
on Thursday, November 5, 2015, followed the same day by a
conference call and live webcast scheduled for 4:30 p.m. ET.
The conference call may be accessed by dialing (877) 312-7507
from the U.S. and Canada, or (631) 813-4828 from international
locations. The conference ID is 67983411. A live webcast will be
available on the Investor Relations section of the corporate
website at http://www.psivida.com.
A replay of the call will be available beginning November 5,
2015, at approximately 7:30 p.m. ET and ending on November 12,
2015, at 11:59 p.m. ET. The replay may be accessed by dialing (855)
859-2056 within the U.S. and Canada or (404) 537-3406 from
international locations, Conference ID Number: 67983411. A replay
of the webcast will also be available on the corporate website
during that time.
About pSivida Corp.pSivida Corp.
(www.psivida.com), headquartered in Watertown, MA, is a leader in
the development of sustained release, drug delivery products for
treating eye diseases. pSivida has developed three of only four
FDA-approved treatments for back-of-the-eye diseases. The most
recent, ILUVIEN®, a micro-insert for diabetic macular edema,
licensed to Alimera Sciences, is currently sold in the U.S. and
three EU countries. Retisert®, an implant for posterior uveitis, is
licensed to and sold by Bausch & Lomb. pSivida’s lead
product candidate, Medidur™, a micro-insert for posterior uveitis
being independently developed, is currently in pivotal Phase III
clinical trials, with an NDA anticipated in the first half of 2017.
pSivida’s pre-clinical development program is focused on using its
core platform technologies Durasert™ and Tethadur™ to deliver drugs
and biologics to treat wet and dry age-related macular
degeneration, glaucoma, osteoarthritis and other diseases. To learn
more about pSivida please visit www.psivida.com and connect on
Twitter, LinkedIn, Facebook and Google+.
SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION
REFORM ACT OF 1995: Various statements made in this release are
forward-looking, and are inherently subject to risks, uncertainties
and potentially inaccurate assumptions. All statements that address
activities, events or developments that we intend, expect or
believe may occur in the future are forward-looking statements.
Some of the factors that could cause actual results to differ
materially from the anticipated results or other expectations
expressed, anticipated or implied in our forward-looking statements
include uncertainties with respect to: our ability to achieve
profitable operations and access to capital; further impairment of
our intangible assets; fluctuations in our operating results;
declines in Retisert royalties; successful commercialization of,
and receipt of revenues from, ILUVIEN for DME; the effect of
pricing and reimbursement decisions on sales of ILUVIEN for DME;
consequences of flucinolone acetonide side effects; safety and
efficacy results of Medidur Phase III trials, timing of filing and
acceptance of the Medidur NDA, if at all; ability to use data in a
U.S. NDA from trials outside the U.S.; any exercise by Pfizer of
its option with respect to the Latanoprost product; our ability to
develop Tethadur to successfully deliver large biologic molecules
and develop products using it; our ability to successfully develop
product candidates, initiate and complete clinical trials and
receive regulatory approvals; our ability to market and sell
products; the success of current and future license agreements;
termination or breach of current license agreements; effects of
competition and other developments affecting sales of products;
market acceptance of products; effects of guidelines,
recommendations and studies; protection of intellectual property
and avoiding intellectual property infringement; retention of key
personnel; product liability; industry consolidation; compliance
with environmental laws; manufacturing risks; risks and costs of
international business operations; legislative or regulatory
changes; volatility of stock price; possible dilution; absence of
dividends; and other factors described in our filings with
the SEC. You should read and interpret any forward-looking
statements in light of these risks. Should known or unknown risks
materialize, or should underlying assumptions prove inaccurate,
actual results could differ materially from past results and those
anticipated, estimated or projected in the forward-looking
statements. You should bear this in mind as you consider any
forward-looking statements. Our forward-looking statements speak
only as of the dates on which they are made. We do not undertake
any obligation to publicly update or revise our forward-looking
statements, even if experience or future changes makes it clear
that any projected results expressed or implied in such statements
will not be realized.
Martin E. Janis & Company, Inc.
Beverly Jedynak
President
+1 312 943 1123
M: +1 773 350 5793
bjedynak@janispr.com
Psivida Corp (ASX:PVA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Psivida Corp (ASX:PVA)
Historical Stock Chart
From Jul 2023 to Jul 2024